rss
J Neurol Neurosurg Psychiatry 2000;68:690 doi:10.1136/jnnp.68.6.690
  • Editorial commentary

Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)

  1. PAUL A T KELLY
  1. Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UKpk@skull.den.ed.ac.uk

      In the paper by Gouzoulis-Mayfrank et al (this issue, pp 719–725)1, the authors provide evidence that even moderate use of the recreational drug methylenedioxymethamphetamine (MDMA) may lead to cognitive decline in otherwise healthy young people.

      This amphetamine derivative (known widely as ecstasy, XTC, or E, but also as Adam, clarity, or essence) is widely used by young people throughout western Europe and the United States. The popularity of the drug has been enhanced by its close …

      [Full text of this article]

      This Article

      1. Extract
      2. Full text

      Responses

      1. Submit a response
      2. No responses published

      Register for free content

      The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

      BMJ Careers - Latest neurology and neurosurgery jobs